[Form 4] NeuroOne Medical Technologies Corporation Insider Trading Activity

Rhea-AI Filing Summary

NeuroOne Medical Technologies Corp. (NMTC) – Form 4 Insider Transaction

Director Edward Andrle was granted an option to purchase 50,000 shares of NMTC common stock on 06/23/2025 at an exercise price of $0.662 per share. The option vests in 12 equal monthly installments—effectively 4,167 options per month—through 06/23/2026 and carries a 10-year expiration ending 06/23/2035. Following this grant, Andrle now beneficially owns 50,000 derivative securities, recorded as direct ownership. No non-derivative share transactions were reported.

The filing signals routine director equity compensation, aligning the director’s incentives with shareholder returns while introducing a modest potential dilution of up to 50,000 shares if the options are fully exercised.

Positive

• Director’s equity stake increases, enhancing alignment between board oversight and shareholder interests.
• One-year monthly vesting incentivizes consistent board engagement throughout the next 12 months.

Negative

• Potential dilution of up to 50,000 shares if all options are exercised.
• Exercise price of $0.662 could be viewed as low if the market price appreciably exceeds this level, potentially increasing dilution impact.

Insights

Equity Compensation Analyst

TL;DR – Standard director option grant; modest size, aligns interests, minimal dilution risk.

The award of 50,000 at-the-money options at $0.662 is a customary incentive structure for early-stage med-tech firms. Vesting over one year encourages near-term engagement, while the 10-year term provides long-run upside. The absence of share sales suggests the director’s net exposure to NMTC equity increased. Relative to typical small-cap float sizes, a 50,000-share potential issuance is generally immaterial to dilution, but still adds incremental supply. Overall, the transaction is neutral-to-positive for governance, with limited market impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrle Edward

(Last) (First) (Middle)

C/O NEUROONE MEDICAL TECHNOLOGIES CORP

7599 ANAGRAM DRIVE

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.662	06/23/2025		A		50,000		(1)	06/23/2035	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.

	/s/ Emily Johns, by Power of Attorney	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NMTC disclose in the latest Form 4?

Director Edward Andrle received an option to buy 50,000 NMTC shares at $0.662 on 06/23/2025.

When do the new NMTC director options vest?

The option vests in 12 equal monthly installments ending around 06/23/2026.

What is the expiration date of the NMTC stock option grant?

The option expires on 06/23/2035, providing a 10-year exercise window.

Does the filing report any NMTC share sales by the director?

No. The Form 4 only reports an option grant, no sales or non-derivative acquisitions/disposals.

How many derivative securities does the director own after the grant?

Edward Andrle now beneficially owns 50,000 NMTC derivative securities (stock options).